Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case
Tweet Send to a Friend
Goldman Sachs downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $26.00 (from $34.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
